LES LSS Webinar: IP and Startup Valuation in Times of Crisis

Intellectual property (IP) accounts for a significant portion of the corporate value of Biotech, Pharmaceutical and Medical Device companies, particularly in the early, pre-revenue stage. It is the main asset by which startups leverage funding, generate revenues or manage to secure a successful exit. That being said, the recent COVID-19 pandemic has heightened some of the frictions surrounding IP and technology monetization rights, particularly when it comes to inventions resulting from federally-funded R&D. This webinar will explore the critical relationship between IP and valuation in the life sciences sector, while focusing on the unique role IP plays in startup funding and exits (M&A or IPO). Through case studies and industry metrics, we will explore some of the key IP valuation models, how they are impacted by recent events (such as the COVD-19 epidemic), and what can be done to optimize valuation and return on investment in times of crisis. 

Key learnings objectives include:
- Trends in early stage life-sciences company valuations and exits.
- The correlation between life-science company valuations and their IP positions.
- The impact of IP position on startup valuations: lessons learned from the Unicorns
- Recent IP developments related to COVID-19 and their potential impact on technology transfer, IP valuation and startup funding and exits in the life sciences sector.

Members: Free

Nonmembers: $69